Wird geladen...
Systemic vasculitis associated with vemurafenib treatment: Case report and literature review
RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Health
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5120889/ https://ncbi.nlm.nih.gov/pubmed/27861332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004988 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|